Trevi Therapeutics Inc (NASDAQ: TRVI): Are We Watching A Disaster Or Are We Buying A Gold Mine?

In the last trading session, 1.61 million shares of the Trevi Therapeutics Inc (NASDAQ:TRVI) were traded, and its beta was 0.87. Most recently the company’s share price was $3.36, and it changed around -$0.09 or -2.61% from the last close, which brings the market valuation of the company to $231.71M. TRVI currently trades at a discount to its 52-week high of $4.00, offering almost -19.05% off that amount. The share price’s 52-week low was $0.97, which indicates that the current value has risen by an impressive 71.13% since then. We note from Trevi Therapeutics Inc’s average daily trading volume that its 10-day average is 0.39 million shares, with the 3-month average coming to 276.99K.

Trevi Therapeutics Inc (NASDAQ:TRVI) trade information

Instantly TRVI has showed a red trend with a performance of -2.61% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 150.75% year-to-date, but still down -6.41% over the last five days. On the other hand, Trevi Therapeutics Inc (NASDAQ:TRVI) is 15.07% up in the 30-day period. We can see from the shorts that 1.07 million shares have been sold at a short interest cover period of 2.41 day(s).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 72.0% from its current value. Analyst projections state that TRVI is forecast to be at a low of $12 and a high of $12.

Trevi Therapeutics Inc (TRVI) estimates and forecasts

Trevi Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 47.69 percent over the past six months and at a -34.48% annual growth rate that is well below the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -50.00% in revenue this quarter, and will report a decrease of -42.90% in the next quarter.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 27.24%.

TRVI Dividends

Trevi Therapeutics Inc’s next quarterly earnings report is expected to be released around May 09 and May 13.

Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.28% of Trevi Therapeutics Inc shares, and 80.44% of them are in the hands of institutional investors. The stock currently has a share float of 81.49%. Trevi Therapeutics Inc stock is held by 93 institutions, with NEA Management Company, LLC being the largest institutional investor. By Jun 29, 2023, it held 17.81% of the shares, which is about 11.37 million shares worth $27.18 million.

Frazier Life Sciences Management, L.P., with 10.78% or 6.88 million shares worth $16.45 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 29, 2023. The former held 1.23 million shares worth $2.94 million, making up 1.93% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 0.91 million shares worth around $2.0 million, which represents about 1.42% of the total shares outstanding.